These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 27394959)

  • 1. Nuclear and extranuclear-initiated estrogen receptor signaling crosstalk and endocrine resistance in breast cancer.
    Kulkoyluoglu E; Madak-Erdogan Z
    Steroids; 2016 Oct; 114():41-47. PubMed ID: 27394959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer.
    Lykkesfeldt AE
    Acta Oncol; 1996; 35 Suppl 5():9-14. PubMed ID: 9142958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen.
    Jang ER; Lim SJ; Lee ES; Jeong G; Kim TY; Bang YJ; Lee JS
    Oncogene; 2004 Mar; 23(9):1724-36. PubMed ID: 14676837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic targeting in the estrogen receptor hormonal pathway.
    Katzenellenbogen BS; Frasor J
    Semin Oncol; 2004 Feb; 31(1 Suppl 3):28-38. PubMed ID: 15052541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V; Gougelet A; Maillard S; Renoir JM
    Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of tamoxifen resistance.
    Ring A; Dowsett M
    Endocr Relat Cancer; 2004 Dec; 11(4):643-58. PubMed ID: 15613444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer.
    Girault I; Bièche I; Lidereau R
    Maturitas; 2006 Jul; 54(4):342-51. PubMed ID: 16822624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer.
    Hanstein B; Djahansouzi S; Dall P; Beckmann MW; Bender HG
    Eur J Endocrinol; 2004 Mar; 150(3):243-55. PubMed ID: 15012607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of the antiestrogenic cajanin stilbene acid towards breast cancer.
    Fu Y; Kadioglu O; Wiench B; Wei Z; Wang W; Luo M; Yang X; Gu C; Zu Y; Efferth T
    J Nutr Biochem; 2015 Nov; 26(11):1273-82. PubMed ID: 26365581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
    McDaniel RE; Maximov PY; Jordan VC
    Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy.
    Yu E; Xu Y; Shi Y; Yu Q; Liu J; Xu L
    J Mol Model; 2019 Aug; 25(9):278. PubMed ID: 31463793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC; Johnston SR; Smith IE; Dowsett M
    Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanisms.
    Bianco S; Gévry N
    Transcription; 2012; 3(4):165-70. PubMed ID: 22771991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors.
    Suba Z
    Recent Pat Anticancer Drug Discov; 2018; 13(4):428-444. PubMed ID: 30027855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Closer Look at Estrogen Receptor Mutations in Breast Cancer and Their Implications for Estrogen and Antiestrogen Responses.
    Clusan L; Le Goff P; Flouriot G; Pakdel F
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33451133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance.
    Busch S; Sims AH; Stål O; Fernö M; Landberg G
    Cancer Res; 2015 Apr; 75(7):1457-69. PubMed ID: 25833830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
    Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
    Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological mechanisms and clinical implications of endocrine resistance in breast cancer.
    Giuliano M; Schifp R; Osborne CK; Trivedi MV
    Breast; 2011 Oct; 20 Suppl 3():S42-9. PubMed ID: 22015292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.